Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib

The most frequent BCR-ABL1-p210 transcripts in chronic myeloid leukemia (CML) are e14a2 and e13a2. Imatinib (IM) is the common first-line tyrosine–kinase inhibitor (TKI) used to treat CML. Some studies suggest that BCR-ABL1 transcript types confer different responses IM. objective of this study was correlate expression or e13a2 clinical characteristics, cumulative cytogenetic molecular IM, acquisition deep response (DMR) its duration (sDMR), progression rate (CIP), overall survival (OS), treatment-free remission (TFR) rate. We studied 202 CML patients, 76 expressing 126 e14a2, correlated differential with above-mentioned parameters. There were no differences incidence nor DMR sDMR between two groups, but had a positive impact on during first 6 months, whereas associated improved long-term OS. No correlation observed type TFR